163 related articles for article (PubMed ID: 31564969)
1. Asunercept as an innovative therapeutic approach for recurrent glioblastoma and other malignancies.
Krendyukov A; Gieffers C
Cancer Manag Res; 2019; 11():8095-8100. PubMed ID: 31564969
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma.
Blaes J; Thomé CM; Pfenning PN; Rübmann P; Sahm F; Wick A; Bunse T; Schmenger T; Sykora J; von Deimling A; Wiestler B; Merz C; Jugold M; Haberkorn U; Abdollahi A; Debus J; Gieffers C; Kunz C; Bendszus M; Kluge M; Platten M; Fricke H; Wick W; Lemke D
Mol Cancer Res; 2018 May; 16(5):767-776. PubMed ID: 29453321
[TBL] [Abstract][Full Text] [Related]
3. Neutralization of the CD95 ligand by APG101 inhibits invasion of glioma cells in vitro.
Merz C; Strecker A; Sykora J; Hill O; Fricke H; Angel P; Gieffers C; Peterziel H
Anticancer Drugs; 2015 Aug; 26(7):716-27. PubMed ID: 25850884
[TBL] [Abstract][Full Text] [Related]
4. The dual role of the CD95 and CD95L signaling pathway in glioblastoma.
Zhang Y; Jin T; Dou Z; Wei B; Zhang B; Sun C
Front Immunol; 2022; 13():1029737. PubMed ID: 36505426
[TBL] [Abstract][Full Text] [Related]
5. CRISPR/Cas9-mediated abrogation of CD95L/CD95 signaling-induced glioma cell growth and immunosuppression increases survival in murine glioma models.
Quijano-Rubio C; Silginer M; Weller M
J Neurooncol; 2022 Nov; 160(2):299-310. PubMed ID: 36355258
[TBL] [Abstract][Full Text] [Related]
6. CD95 gene deletion may reduce clonogenic growth and invasiveness of human glioblastoma cells in a CD95 ligand-independent manner.
Quijano-Rubio C; Silginer M; Weller M
Cell Death Discov; 2022 Jul; 8(1):341. PubMed ID: 35906203
[TBL] [Abstract][Full Text] [Related]
7. [Cytofluorometric analysis of chosen markers of apoptosis CD95/CD95L (Fas/FasL) in thyroid tissues from young patients with Graves' disease and Hashimoto's thyroiditis].
Bossowski A; Stasiak-Barmuta A; Czarnocka B; Urban M; Łyczkowska A; Niedziela M; Bardadin K; Czerwińska J; Dadan J; Baltaziak M
Endokrynol Diabetol Chor Przemiany Materii Wieku Rozw; 2006; 12(2):83-90. PubMed ID: 16813711
[TBL] [Abstract][Full Text] [Related]
8. CD95L and Anti-Tumor Immune Response: Current Understanding and New Evidence.
Richards DM; Merz C; Gieffers C; Krendyukov A
Cancer Manag Res; 2021; 13():2477-2482. PubMed ID: 33758545
[TBL] [Abstract][Full Text] [Related]
9. CD95 ligand: lethal weapon against malignant glioma?
Weller M; Kleihues P; Dichgans J; Ohgaki H
Brain Pathol; 1998 Apr; 8(2):285-93. PubMed ID: 9546287
[TBL] [Abstract][Full Text] [Related]
10. Functional CD95 ligand and CD95 death-inducing signaling complex in activation-induced cell death and doxorubicin-induced apoptosis in leukemic T cells.
Fulda S; Strauss G; Meyer E; Debatin KM
Blood; 2000 Jan; 95(1):301-8. PubMed ID: 10607716
[TBL] [Abstract][Full Text] [Related]
11. CD95/Fas signaling in human melanoma cells: conditional expression of CD95L/FasL overcomes the intrinsic apoptosis resistance of malignant melanoma and inhibits growth and progression of human melanoma xenotransplants.
Eberle J; Fecker LF; Hossini AM; Wieder T; Daniel PT; Orfanos CE; Geilen CC
Oncogene; 2003 Dec; 22(57):9131-41. PubMed ID: 14668794
[TBL] [Abstract][Full Text] [Related]
12. Production and pro-apoptotic activity of soluble CD95 ligand in pancreatic carcinoma.
Bellone G; Smirne C; Carbone A; Mareschi K; Dughera L; Farina EC; Alabiso O; Valente G; Emanuelli G; Rodeck U
Clin Cancer Res; 2000 Jun; 6(6):2448-55. PubMed ID: 10873098
[TBL] [Abstract][Full Text] [Related]
13. Peripheral T and putative natural killer cell lymphomas commonly coexpress CD95 and CD95 ligand.
Ng CS; Lo ST; Chan JK
Hum Pathol; 1999 Jan; 30(1):48-53. PubMed ID: 9923926
[TBL] [Abstract][Full Text] [Related]
14. Treatment with the apoptosis inhibitor Asunercept reduces clone sizes in patients with lower risk Myelodysplastic Neoplasms.
Streuer A; Jann JC; Boch T; Mossner M; Riabov V; Schmitt N; Altrock E; Xu Q; Demmerle M; Nowak V; Oblaender J; Palme I; Weimer N; Rapp F; Metzgeroth G; Hecht A; Höger T; Merz C; Hofmann WK; Nolte F; Nowak D
Ann Hematol; 2024 Apr; 103(4):1221-1233. PubMed ID: 38413410
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS.
Boch T; Luft T; Metzgeroth G; Mossner M; Jann JC; Nowak D; Meir F; Schumann C; Klemmer J; Brendel S; Fricke H; Kunz C; Weiß C; Hofmann WK; Nolte F
Leuk Res; 2018 May; 68():62-69. PubMed ID: 29549809
[TBL] [Abstract][Full Text] [Related]
16. CD95/Fas, Non-Apoptotic Signaling Pathways, and Kinases.
Le Gallo M; Poissonnier A; Blanco P; Legembre P
Front Immunol; 2017; 8():1216. PubMed ID: 29021794
[TBL] [Abstract][Full Text] [Related]
17. CD95 ligand is a proliferative and antiapoptotic signal in quiescent hepatic stellate cells.
Reinehr R; Sommerfeld A; Häussinger D
Gastroenterology; 2008 May; 134(5):1494-506. PubMed ID: 18471522
[TBL] [Abstract][Full Text] [Related]
18. A phase II, randomized, study of weekly APG101+reirradiation versus reirradiation in progressive glioblastoma.
Wick W; Fricke H; Junge K; Kobyakov G; Martens T; Heese O; Wiestler B; Schliesser MG; von Deimling A; Pichler J; Vetlova E; Harting I; Debus J; Hartmann C; Kunz C; Platten M; Bendszus M; Combs SE
Clin Cancer Res; 2014 Dec; 20(24):6304-13. PubMed ID: 25338498
[TBL] [Abstract][Full Text] [Related]
19. Expression of Fas ligand (CD95L) in primary malignant melanoma and melanoma metastases is associated with overall survival.
Neuber K; Eidam B
Onkologie; 2006 Sep; 29(8-9):361-5. PubMed ID: 16974112
[TBL] [Abstract][Full Text] [Related]
20. Safety and tolerability of asunercept plus standard radiotherapy/temozolomide in Asian patients with newly-diagnosed glioblastoma: a phase I study.
Wei KC; Hsu PW; Tsai HC; Lin YJ; Chen KT; Toh CH; Huang HL; Jung SM; Tseng CK; Ke YX
Sci Rep; 2021 Dec; 11(1):24067. PubMed ID: 34911992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
